Literature DB >> 27742011

Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.

Sebastien Boucle1, Leda Bassit1, Maryam Ehteshami1, Raymond F Schinazi2.   

Abstract

Hepatitis B virus (HBV) causes significant morbidity and mortality worldwide. The majority of chronically infected individuals do not achieve a functional and complete cure. Treated persons who achieve a long-term sustained virologic response (undetectable HBV DNA), are still at high risk of developing morbidity and mortality from liver complications. This review focuses on novel, mechanistically diverse anti-HBV therapeutic strategies currently in development or in clinical evaluation, and highlights new combination strategies that may contribute to full elimination of HBV DNA and covalently closed circular DNA from the infected liver, leading to a complete cure of chronic hepatitis B.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-HBV agents; Antiviral therapy; CRISPR/Cas9; HBV cure; HBsAg; cccDNA; siRNA

Mesh：

Substances：

Year:  2016        PMID： 27742011      PMCID： PMC5119551          DOI： 10.1016/j.cld.2016.07.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


  38 in total

1.  In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations.

Authors:  Xue-Yan Wang; Zhen-Man Wei; Guo-Yi Wu; Jiang-Hua Wang; Ying-Jun Zhang; Jing Li; Heng-Hui Zhang; Xing-Wang Xie; Xian Wang; Zhao-He Wang; Lai Wei; Yu Wang; Hong-Song Chen
Journal:  Antivir Ther       Date:  2012-06-06

Review 2.  Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.

Authors:  Robert G Gish; Man-Fung Yuen; Henry Lik Yuen Chan; Bruce D Given; Ching-Lung Lai; Stephen A Locarnini; Johnson Y N Lau; Christine I Wooddell; Thomas Schluep; David L Lewis
Journal:  Antiviral Res       Date:  2015-06-27       Impact factor: 5.970

3.  Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase.

Authors:  Judit Vörös; Annika Urbanek; Gilles Jean Philippe Rautureau; Maggie O'Connor; Henry C Fisher; Alison E Ashcroft; Neil Ferguson
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

Review 4.  Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs.

Authors:  Stephen Locarnini; Angelos Hatzakis; Ding-Shinn Chen; Anna Lok
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

5.  The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.

Authors:  Gaëtan Billioud; Christian Pichoud; Gerhard Puerstinger; Johan Neyts; Fabien Zoulim
Journal:  Antiviral Res       Date:  2011-08-18       Impact factor: 5.970

Review 6.  Recent developments in antivirals against hepatitis B virus.

Authors:  Ya-Juan Wang; Li Yang; Jian-Ping Zuo
Journal:  Virus Res       Date:  2015-12-28       Impact factor: 3.303

7.  Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

Authors:  Patrick Marcellin; Sang Hoon Ahn; Xiaoli Ma; Florin A Caruntu; Won Young Tak; Magdy Elkashab; Wan-Long Chuang; Seng-Gee Lim; Fehmi Tabak; Rajiv Mehta; Joerg Petersen; Graham R Foster; Lillian Lou; Eduardo B Martins; Phillip Dinh; Lanjia Lin; Amoreena Corsa; Prista Charuworn; G Mani Subramanian; Hans Reiser; Hendrick W Reesink; Scott Fung; Simone I Strasser; Huy Trinh; Maria Buti; Giovanni B Gaeta; Aric J Hui; George Papatheodoridis; Robert Flisiak; Henry L Y Chan
Journal:  Gastroenterology       Date:  2015-10-08       Impact factor: 22.682

8.  HBV life cycle: entry and morphogenesis.

Authors:  Stephanie Schädler; Eberhard Hildt
Journal:  Viruses       Date:  2009-09-01       Impact factor: 5.048

9.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.

Authors:  Su-Ru Lin; Hung-Chih Yang; Yi-Ting Kuo; Chun-Jen Liu; Ta-Yu Yang; Ku-Chun Sung; You-Yu Lin; Hurng-Yi Wang; Chih-Chiang Wang; Yueh-Chi Shen; Fang-Yi Wu; Jia-Horng Kao; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-19       Impact factor: 10.183

Review 10.  Anti-HBV Drugs: Progress, Unmet Needs, and New Hope.

Authors:  Lei Kang; Jiaqian Pan; Jiaofen Wu; Jiali Hu; Qian Sun; Jing Tang
Journal:  Viruses       Date:  2015-09-15       Impact factor: 5.048
View more
  13 in total

1.  Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors.

Authors:  Sebastien Boucle; Xiao Lu; Leda Bassit; Tugba Ozturk; Olivia Ollinger Russell; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  Bioorg Med Chem Lett       Date:  2017-01-06       Impact factor: 2.823

Review 2.  From HCV To HBV Cure.

Authors:  Raymond F Schinazi; Tarik Asselah
Journal:  Liver Int       Date:  2017-01       Impact factor: 5.828

3.  Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice.

Authors:  Franck Amblard; Sebastien Boucle; Leda Bassit; Bryan Cox; Ozkan Sari; Sijia Tao; Zhe Chen; Tugba Ozturk; Kiran Verma; Olivia Russell; Virgile Rat; Hugues de Rocquigny; Oriane Fiquet; Maud Boussand; James Di Santo; Helene Strick-Marchand; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 4.  Ideal Cure for Hepatitis B Infection: The Target is in Sight.

Authors:  Shrihari A Anikhindi; Ashish Kumar; Praveen Sharma; Vikas Singla; Naresh Bansal; Anil Arora
Journal:  J Clin Exp Hepatol       Date:  2017-11-07

5.  Effect of modified Xiaochaihu decoction‑containing serum on HepG2.2.15 cells via the JAK2/STAT3 signaling pathway.

Authors:  Shaofang Chen; Zhanglin Wang; Shichuan Wan; Hai Huang; Huiqing Liang
Journal:  Mol Med Rep       Date:  2017-09-20       Impact factor: 2.952

6.  Prevalence and genetic diversity of HCV among HIV-1 infected individuals living in Ahvaz, Iran.

Authors:  Ali Teimoori; Saeedeh Ebrahimi; Narges Keshtkar; Soheila Khaghani; Shokrollah Salmanzadeh; Shokouh Ghafari
Journal:  BMC Infect Dis       Date:  2019-05-08       Impact factor: 3.090

Review 7.  2019 meeting of the global virus network.

Authors:  Ramesh Akkina; Robert Garry; Christian Bréchot; Heinz Ellerbrok; Hideki Hasegawa; Luis Menéndez-Arias; Natalia Mercer; Johan Neyts; Victor Romanowski; Joaquim Segalés; Anders Vahlne
Journal:  Antiviral Res       Date:  2019-11-04       Impact factor: 5.970

Review 8.  Pharmacological plasticity-How do you hit a moving target?

Authors:  Michael J Parnham; Gerd Geisslinger
Journal:  Pharmacol Res Perspect       Date:  2019-11-21

9.  Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.

Authors:  Teresa Broquetas; Montserrat Garcia-Retortillo; Juan José Hernandez; Marc Puigvehí; Nuria Cañete; Susana Coll; Beatriz Cabrero; Maria Dolors Giménez; Ricard Solà; José A Carrión
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

10.  An Immortalized Hepatocyte-like Cell Line (imHC) Accommodated Complete Viral Lifecycle, Viral Persistence Form, cccDNA and Eventual Spreading of a Clinically-Isolated HBV.

Authors:  Khanit Sa-Ngiamsuntorn; Piyanoot Thongsri; Yongyut Pewkliang; Adisak Wongkajornsilp; Pattida Kongsomboonchoke; Phichaya Suthivanich; Suparerk Borwornpinyo; Suradej Hongeng
Journal:  Viruses       Date:  2019-10-16       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.